Sponsors should flag decentralized aspects of cancer trials to prep for the post-Covid era, FDA says

Sponsors should flag decentralized aspects of cancer trials to prep for the post-Covid era, FDA says

Source: 
Endpoints
snippet: 

As more and more clinical trials during the pandemic have harnessed the power of remote assessments and modifications, the FDA Oncology Center of Excellence and the Office of Oncologic Diseases are now requesting that applicants voluntarily add flags to datasets to discriminate between remote assessments and trial site assessments.